B-Cell Lymphoma/leukemia 10 (BCL10) Antibody

Este producto es parte de BCL10 immune signaling adaptor
B-Cell Lymphoma/leukemia 10 (BCL10) Antibody

Pida mas información

935106861

info@markelab.com

Precio

383.5€ (100 µl)

Antibody anti-BCL10

proveedor

Abbexa

reference

abx015774

Tested Applications

ELISA, WB, IHC, IF/ICC, FCM

reactivity

Human, Mouse

status

RUO

clonality

Monoclonal

Descripción

Bcl-10 (B-cell CLL/lymphoma 10), also known as CLAP, Me10, CIPER, c-E10, CARMEN.Entrez Protein NP_003912.It is a protein containing a caspase recruitment domain (CARD).It plays an important role in apoptosis and activating NF-kappaB.The research suggested that it interacted with other CARD domain containing proteins including CARD9, 10, 11 and 14, which were thought to function as upstream regulators in NF-kappaB signaling.Bcl-10 is found to form a complex with MALT1 which encoded by another gene known to be translocated in MALT lymphoma.MALT1 and Bcl-10 are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy.


Background

B-cell lymphoma/leukemia 10 (BCL10) is an essential signaling molecule involved in the regulation of immune cell activation, particularly in T-cell and B-cell responses BCL10 functions as a scaffolding protein in the activation of the NF-κB pathway, which is crucial for regulating inflammation, immune responses, and cell survival BCL10 forms a complex with other proteins, such as MALT1, to initiate signaling cascades that lead to immune cell activation and proliferation Its dysregulation has been linked to lymphoid malignancies, such as MALT lymphoma, where mutations or overexpression of BCL10 promote cancer cell proliferation and survival BCL10 is also involved in the regulation of apoptosis and cell differentiation, particularly in the context of immune cell maturation In addition to its role in immune cells, BCL10 has been shown to influence inflammatory diseases and autoimmunity, making it a potential target for therapeutic intervention

Características del producto

category

Primary Antibodies


clonality

Monoclonal


reactivity

Human, Mouse


immunogen target

B-Cell Lymphoma/leukemia 10 (BCL10)


host

Mouse


isotype

IgG1


conjugation

Unconjugated


form

Liquid


tested applications

ELISA, WB, IHC, IF/ICC, FCM


purification

Unpurified ascites.


recommended dilution

ELISA: 1/10000, WB: 1/500 - 1/2000, IHC: 1/200 - 1/1000, IF/ICC: 1/200 - 1/1000, FCM: 1/200 - 1/400. Optimal dilutions/concentrations should be determined by the end user.


buffer

Ascitic fluid containing 0.03% sodium azide.


size 1

100 µl


storage

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.


or code

BCL10


dry ice

No


availability

Shipped within 5-10 working days.


alias

CARMEN,CIPER,CLAP,IMD37,c-E10 Me10,CARD-containing molecule enhancing NF-kappa-B,CARD-like apoptotic protein, hCLAP


note

Concentration: Not determined. -


Quizá le pueda interesar

Rat Bcl10(B-cell lymphoma/leukemia 10) ELISA Kit

Rat Bcl10(B-cell lymphoma/leukemia 10) ELISA Kit

proveedor

FineTest

reference

ER0707

reactivity

rat

status

RUO

Precio a consultar

Ver más

anti- BCL10 antibody

anti- BCL10 antibody

proveedor

FineTest

reference

FNab00835

Tested Applications

ELISA, WB, IHC

reactivity

human,mouse,rat

status

RUO

clonality

polyclonal

Involved in adaptive immune response(PubMed:25365219). Promotes apoptosis, pro-caspase-9 maturation and activation of NF...

Precio a consultar

Ver más

anti- BCL10 antibody

anti- BCL10 antibody

proveedor

FineTest

reference

FNab00836

Tested Applications

ELISA, WB, IHC

reactivity

human,mouse

status

RUO

clonality

polyclonal

Involved in adaptive immune response(PubMed:25365219). Promotes apoptosis, pro-caspase-9 maturation and activation of NF...

Precio a consultar

Ver más